Profound Medical Corp.

Company Overview

Business Model: Profound Medical Corp. is a commercial-stage medical device company specializing in AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The business model comprises two primary revenue streams: sales of capital equipment and recurring non-capital revenue from one-time-use devices and related services.

Market Position: Profound Medical Corp. offers two platform technologies: the TULSA-PRO system and the Sonalleve system. The TULSA-PRO system is the lead product, cleared by the FDA as a Class II device in the United States for thermal ablation of prescribed prostate tissue, CE Marked in the EU for ablation of targeted prostate tissue (benign or malignant), and approved by Health Canada as a Class III device. The Sonalleve system is CE Marked in the EU for ablation of uterine fibroids, adenomyotic tissue, palliative pain relief for bone metastases, osteoid osteoma, and benign desmoid tumors. It is also approved in China and South Korea for uterine fibroids and holds FDA HDE approval for osteoid osteoma in the extremities. Both systems are compatible with select MRI scanners from Philips, Siemens, and GE Healthcare.

Recent Strategic Developments:

• Clinical Trial Milestones: Enrollment and treatment for the CAPTAIN trial (comparing TULSA procedure to robotic radical prostatectomy for localized prostate cancer) were completed in 2025 with 211 subjects. Perioperative outcomes presented in 2025 demonstrated the TULSA procedure's superiority over robotic prostatectomy in blood loss, length of stay, post-procedure pain, and recovery to baseline activities and overall health.
• Commercial Partnerships: In December 2024, Profound Medical Corp. announced a definitive co-sales and co-marketing agreement with Siemens Healthineers to offer a complete solution for MRI-guided prostate therapy. This builds on a December 2020 co-development agreement with GE Healthcare, which expanded TULSA-PRO system compatibility to GE Healthcare MRI scanners, with the first site agreement signed in March 2022 for 3T MRI scanners.
• Reimbursement Enhancements: Effective January 1, 2025, the U.S. Centers for Medicare and Medicaid Services (CMS) established Category 1 CPT codes for the TULSA procedure. These include codes 51721 (TULSA Device Management), 55881 (TULSA Treatment, two physicians), and 55882 (TULSA Complete Procedure, single physician), all with a 0-day global period. The Final Rule for Hospital Payment established CPT 55882 as a Level 7 Urology Ambulatory Payment Classification (APC) with a Medicare National Average payment of $13,479. For Ambulatory Surgical Centers (ASCs), the facility payment for CPT 55882 is $10,874. These rates are noted as higher than mainstream prostate cancer and BPH treatments.
• Capital Raises: In December 2025, Profound Medical Corp. completed a public offering and a private placement, raising net proceeds of $40.8 million to fund continued commercialization of the TULSA-PRO system in the United States, global development and commercialization of both systems, and for working capital.

Geographic Footprint: Profound Medical Corp. generates revenue in the United States, EU, and Asia, with a primary commercial focus on the U.S. market. For the year ended December 31, 2025, approximately 76% of revenues were generated in the United States, 5% in the EU, and 19% in Asia. The company has wholly owned subsidiaries in Canada, Finland, Germany, United States, and China.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 71% (2025), 66% (2024)
• Operating Margin: (256.3)% (2025), (309.6)% (2024)
• Net Margin: (264.4)% (2025), (260.4)% (2024)

Investment in Growth:

• R&D Expenditure: $20.6 million (128% of revenue)
• Capital Expenditures: $0.24 million
• Strategic Investments: Significant R&D investment in new product development, continuous product improvement, and clinical trials (e.g., CAPTAIN trial).

Business Segment Analysis

Profound Medical Corp. manages its business as one operating segment focused on medical technology for magnetic resonance guided ablation procedures. The company's operations are driven by two primary product lines: the TULSA-PRO system and the Sonalleve system.

TULSA-PRO System

Financial Performance:

• Revenue: Contributes to total revenue of $16.1 million (+51% YoY).
  • Recurring - non-capital revenue: $9.7 million (2025), $8.2 million (2024)
  • Capital equipment revenue: $6.4 million (2025), $2.4 million (2024)
• Operating Margin: Not segment-specific.
• Key Growth Drivers: Increased selling prices, growth in the number of capital systems sold, and increased commercialization efforts in the United States. Ongoing investment in clinical trials (e.g., CAPTAIN trial) and R&D for product improvement. The introduction of Category 1 CPT codes and favorable reimbursement rates from CMS are expected to drive adoption.

Product Portfolio: The TULSA-PRO system combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound, and closed-loop temperature feedback control. It is designed to ablate whole gland or physician-defined regions of malignant or benign prostate tissue. The system utilizes a one-time-use transurethral catheter and includes a Thermal Boost module for temporarily increasing ablation target temperature in high-risk cancer regions.

Market Dynamics: The TULSA-PRO system is primarily marketed to early adopter urologists and radiologists at opinion-leading hospitals. It competes with various prostate disease treatments including watchful waiting, simple prostatectomy, radical prostatectomy (open, laparoscopic, robotic), radiation therapies (EBRT, brachytherapy, HDR), and focal ablation techniques (cryoablation, trans-rectal HIFU, IRE, water steam ablation). Profound Medical Corp. highlights the TULSA-PRO system's advantages as an incision-free, radiation-free, customizable, and precise therapy with potential for lower post-procedural pain, faster recovery, and reduced side effects.

Clinical Studies:

• TACT Pivotal Clinical Trial: Demonstrated 96% PSA reduction at 12 months (median nadir 0.34 ng/ml) and 0.26 ng/ml at five years. Achieved 91% median decrease in perfused prostate volume at 12 months. Showed high safety and maintenance of quality-of-life, with 96% urinary continence and 75% erectile function at 12 months, improving to 97% and 87% respectively at five years.
• BPH Studies: Two clinical studies showed promising safety and feasibility for relieving Lower Urinary Tract Symptoms (LUTS) associated with BPH, with IPSS improvements comparable to modern minimally invasive surgical therapies.
• Salvage TULSA (sTULSA): Evaluated for radio-recurrent localized prostate cancer, showing a median PSA decrease from 3.3 ng/ml at baseline to 0.05 ng/ml at three months.
• Palliative TULSA (pTULSA): Demonstrated safety and feasibility for symptomatic locally advanced prostate cancer, with 70% of subjects becoming completely catheter-free and 100% free of gross hematuria at last follow-up.
• CAPTAIN Trial: A prospective, multi-center randomized controlled trial comparing TULSA procedure with robotic radical prostatectomy for intermediate-risk prostate cancer. Enrollment and treatment completed in 2025. Perioperative outcomes presented in 2025 indicated TULSA's superiority in blood loss, length of stay, post-procedure pain, and recovery.

Sonalleve System

Financial Performance: Contributes to the company's overall capital equipment and recurring non-capital revenue, primarily in markets outside North America.

• Revenue: Not segment-specific.
• Operating Margin: Not segment-specific.
• Key Growth Drivers: Continued pursuit of additional regulatory approvals in international jurisdictions and exploration of additional potential treatment markets (e.g., non-invasive ablation of abdominal cancers, hyperthermia for cancer therapy).

Product Portfolio: The Sonalleve system combines real-time MRI and thermometry with focused ultrasound delivered from outside the patient to enable precise, incision-free ablation of diseased tissue.

Market Dynamics: The Sonalleve system is CE Marked in the EU for uterine fibroids, adenomyotic tissue, palliative pain relief for bone metastases, osteoid osteoma, and benign desmoid tumors. It is also approved in China and South Korea for non-invasive treatment of uterine fibroids and has FDA HDE approval for osteoid osteoma in the extremities. It competes with hormonal medications, progesterone releasing intra-uterine devices, uterine artery embolization, and surgical procedures (hysterectomy, myomectomy) for uterine fibroids, and surgery and radiofrequency ablation for osteoid osteoma.

Clinical Applications:

• Uterine Fibroids and Adenomyosis: Studies show impressive performance in ablation efficiency, therapeutic efficacy, symptom reduction, and quality of life improvement.
• Palliative Bone Pain Treatment: Clinical evaluation reports and a randomized controlled Phase III study demonstrated significant decrease in pain scores and/or medication dosage and increase in quality of life.
• Osteoid Osteoma Treatment: Studies show high clinical success rates and complete symptom resolution with no serious adverse effects, offering a non-invasive, radiation-free alternative.
• Desmoid Tumor Treatment: Assessed as a non-invasive therapy, showing good clinical success and even complete tumor eradication in some cases with low numbers of mild adverse events.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: Profound Medical Corp. has never declared or paid cash dividends and intends to retain all future earnings to fund business development and growth. No dividends are anticipated in the foreseeable future.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position:

• Cash and Equivalents: $59.7 million (as of December 31, 2025)
• Total Debt: $4.5 million (as of December 31, 2025)
• Net Cash Position: $55.2 million (as of December 31, 2025)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The CIBC Credit Agreement matures on March 3, 2027. Long-term debt obligations include $0.3 million due within one year and $4.6 million due between one and five years.

Cash Flow Generation:

• Operating Cash Flow: $(38.2) million (2025), $(23.5) million (2024)
• Free Cash Flow: $(38.4) million (2025), $(23.5) million (2024) (Operating Cash Flow less Capital Expenditures)
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: Profound Medical Corp. employs a hybrid revenue business model, combining capital equipment sales with recurring revenue from one-time-use devices and services. The company is establishing direct sales and marketing teams to drive adoption, support clinical customers, and increase system utilization.

Supply Chain Architecture: Key Suppliers & Partners:

• Component Suppliers: Standard electronic components are sourced from third-party vendors. Custom system electronics, printed circuit boards, assemblies, and custom mechanical parts are outsourced from approved suppliers. Profound Medical Corp. relies on single-source suppliers for some components.
• Manufacturing Partners: The company intends to partner with additional cGMP-compliant and FDA-registered contract manufacturers for the TULSA-PRO system in the United States.
• Technology Partners: Profound Medical Corp. collaborates with Philips, Siemens, and GE Healthcare for lead generation and distribution of capital equipment, leveraging compatibility with their MRI scanners.

Facility Network:

• Manufacturing: Corporate headquarters in Mississauga, Ontario, Canada, includes approximately 38,148 square feet of office and manufacturing space (lease expires September 2026). An office in Vantaa, Finland, is leased (lease expires December 2026, extended to 2033).
• Research & Development: R&D activities are conducted, but no specific dedicated R&D facilities are detailed beyond general office/manufacturing space.
• Distribution: Not explicitly detailed, but the company is expanding its distribution capacity.

Operational Metrics: Specific operational metrics such as capacity utilization or efficiency measures are not disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Profound Medical Corp. is establishing its own direct sales and marketing teams, particularly for the TULSA-PRO system in the United States.
• Channel Partners: Strategic collaborations exist with Philips, Siemens Healthineers, and GE Healthcare for lead generation and distribution of capital equipment.
• Digital Platforms: Not explicitly detailed.

Customer Portfolio: Enterprise Customers: The TULSA-PRO system is primarily marketed to early adopter physicians, including urologists and radiologists, at opinion-leading hospitals. Services are available at independent imaging centers or hospitals.

• Customer Concentration: Not disclosed.

Geographic Revenue Distribution:

• United States: 76% of total revenue (2025)
• EU: 5% of total revenue (2025)
• Asia: 19% of total revenue (2025)
• Canada: $3.1 million (2025)
• Germany: $0.8 million (2025)

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: Profound Medical Corp. operates in the medical device industry, focusing on MRI-guided ablation therapies. The market addresses significant conditions such as prostate cancer (estimated 333,830 new cases in the United States in 2026, 3.3 million men living with it in the U.S., 5.8 million including the EU) and Benign Prostatic Hyperplasia (BPH), which is nearly ubiquitous in the aging male population. The industry is characterized by evolving standards, market trends, customer preferences, and competitive pricing pressures.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Prostate Disease (TULSA-PRO system):
  • Watchful Waiting/Active Surveillance: For earlier stage, lower risk disease.
  • Surgical Interventions: Simple prostatectomy, radical prostatectomy (open, laparoscopic, robotic).
  • Radiation Therapies: External Beam Radiation Therapy (EBRT), brachytherapy, High Dose Radiation (HDR).
  • Focal Ablation Techniques: Cryoablation, trans-rectal High Intensity Focused Ultrasound (HIFU), Irreversible Electroporation (IRE), water steam ablation.
  • Adjunct/Emerging Therapies: Androgen Deprivation Therapy (ADT), Transurethral Resection of the Prostate (TURP), Proton Beam Therapy.
• Uterine Fibroids (Sonalleve system):
  • Hormonal Medications: Gonadotrophin Releasing Hormone (Gn-RH) agonists, progesterone releasing intra-uterine devices.
  • Interventional Radiology: Uterine artery embolization.
  • Surgical Procedures: Hysterectomy, myomectomy.
• Osteoid Osteoma (Sonalleve system):
  • Surgery, radiofrequency ablation (RFA).

Emerging Competitive Threats: Not explicitly detailed, but the company acknowledges the risk of competitors developing more effective or less expensive products and the need to maintain technological superiority.

Competitive Response Strategy: Profound Medical Corp. aims to achieve and maintain technological superiority through continuous development, testing, and marketing of its products. This includes expanding compatibility with various MRI scanners and leveraging clinical data to support market acceptance and reimbursement.

Risk Assessment Framework

Strategic & Market Risks

• Market Dynamics: Risks include failure to achieve or maintain market acceptance for products, reliance on physician/clinician relationships, potential misuse of products, and the need to expand MRI scanner compatibility.
• Technology Disruption: The industry is subject to changing standards and new technologies, which could render products uncompetitive.
• Customer Concentration: Not explicitly detailed, but general reliance on healthcare providers and third-party payers.

Operational & Execution Risks

• Supply Chain Vulnerabilities: Potential manufacturing scaling issues due to limited experience at commercial scale, reliance on third-party component manufacturers, and dependence on single-source suppliers for some components.
• Geographic Concentration: Operations and sales are international, exposing the company to risks inherent in conducting business abroad, including political and economic instability.
• Capacity Constraints: Challenges in increasing assembly and testing capacity, including hiring and retaining skilled personnel.
• AI Development Risks: Risks associated with the development and use of AI, including security, privacy, compliance, ethical issues, and new regulatory scrutiny.
• Facilities Damage: Risk of delays and revenue impact if manufacturing facilities are damaged or destroyed.
• Acquisition Risks: Risks associated with integrating acquired businesses and technologies, such as the Sonalleve system.
• Labor Relations: A portion of employees are unionized, posing a risk of work stoppages.

Financial & Regulatory Risks

• Market & Financial Risks: Limited operating history and history of operating losses, capital-intensive business requiring significant investment, exposure to foreign currency risk (unhedged), product liability claims, and rising insurance costs.
• Regulatory & Compliance Risks: Extensive government regulation in the U.S. (FDA, FFDCA, QSR/QMSR, GCP), EU (MDD, New EU MDR), Canada (Health Canada), and other jurisdictions. Risks include delays in obtaining regulatory approvals, non-compliance with quality systems, product recalls, medical device reporting, and enforcement actions for off-label promotion. Healthcare reform measures and fraud and abuse laws (Anti-Kickback Statute, False Claims Act, HIPAA, HITECH, Sunshine Act) pose compliance challenges.
• Credit & Liquidity: Future compliance with financial covenants in the CIBC Credit Agreement is dependent on achieving certain revenue, EBITDA, and unrestricted cash levels.

Geopolitical & External Risks

• Geographic Dependencies: International operations are subject to risks such as difficulties in coordinating foreign operations, price and currency exchange controls, differing intellectual property protection, and unexpected regulatory changes.
• Trade Relations: Exposure to currently imposed and potential future tariffs and trade measures (e.g., USMCA).
• Sanctions & Export Controls: Not explicitly detailed, but general international trade risks apply.

Innovation & Technology Leadership

Research & Development Focus: Profound Medical Corp. is committed to ongoing R&D, focusing on new product development, continuous product improvement, and investment in clinical trials. A key area of focus is the integration of AI, including machine learning for automatic prostate segmentation, ultrasound applicator alignment, and prediction of treatment times in the TULSA-PRO system.

Core Technology Areas:

• MRI-Guided Ablation: Utilizing real-time MRI imaging for planning, monitoring, and controlling ultrasonic ablation.
• MRI Thermometry: Methods specifically for ultrasound therapy processes and devices.
• Acoustic Arrays: Phasing, beam-forming, and control of acoustic arrays and similar energy sources.
• Computational Methods: Improving filtering, imaging, and analysis of MRI-guided thermal therapy results.
• Support Systems: Secondary and support systems, such as active cooling of near-target tissues.

Innovation Pipeline: The company continuously invests in R&D and clinical studies to expand the body of evidence for its products, pursue additional regulatory approvals, and potentially expand applications of its platform technology.

Intellectual Property Portfolio: Profound Medical Corp. maintains a broad and global IP portfolio, including approximately 40 patent families, representing around 169 granted or allowed patents and 29 patent applications worldwide. This portfolio covers both the TULSA-PRO and Sonalleve product families, as well as generic technologies and extensions.

• Patent Strategy: The company pursues a global patent strategy, registering for protection in key markets including the United States, Canada, Japan, major European markets, and emerging markets. It also relies on trade secrets and know-how.
• Licensing Programs: Holds an exclusive worldwide and royalty-free license with Sunnybrook Health Sciences Centre for certain technology related to MRI-guided transurethral ultrasound therapy (TULSA-PRO system).

Technology Partnerships: Strategic alliances include co-development and co-marketing agreements with major MRI manufacturers like Philips, Siemens Healthineers, and GE Healthcare to ensure compatibility and expand market reach.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The company invests in the ongoing development of its workforce through various training programs and leadership development initiatives. A clawback policy is in place for NEOs for certain misconduct.

Board Composition: The Board of Directors consists of six members. Five directors are independent: Brian Ellacott (Lead Independent Director), Cynthia Lavoie, Murielle Lortie, Arthur Rosenthal, and Kris Shah. Arun Menawat, the CEO, is a non-independent director. The Board has two women members.

Human Capital Strategy

Workforce Composition:

• Total Employees: 162 (as of December 31, 2025), all full-time.
• Geographic Distribution: Employees are located in various regions, including Vantaa, Finland, where 17 employees are represented by a labor union.
• Skill Mix: Not explicitly detailed, but the company aims to attract and retain qualified personnel with appropriate knowledge, background, and skills in the medical device field.

Talent Management: Acquisition & Retention: The company's human capital objectives include identifying, recruiting, retaining, incentivizing, and integrating employees, advisors, and consultants. It offers competitive compensation and benefits packages, including health insurance and paid time off. Equity and cash incentive plans are used to attract, retain, and reward personnel.

• Retention Metrics: Not disclosed.
• Employee Value Proposition: Profound Medical Corp. invests in ongoing workforce development through training and leadership programs, provides continuous learning tools, and prioritizes employee well-being through flexible work arrangements and wellness programs.

Diversity & Development: The company recognizes diversity as an economic driver and strives to promote an environment conducive to the appointment of well-qualified persons with appropriate diversity. Gender is considered in the selection of candidates for executive officer and senior manager appointments, and Board/committee membership. No specific targets for women on the Board or in executive/senior management positions have been adopted.

Environmental & Social Impact

Environmental Commitments: Profound Medical Corp. uses hazardous materials in its research and development and manufacturing processes and is subject to various regulations governing their use, storage, handling, and disposal. The company needs licenses to handle such materials and aims to retain them.

• Climate Strategy: Not explicitly detailed.
• Supply Chain Sustainability: Not explicitly detailed.

Social Impact Initiatives: Not explicitly detailed.

Business Cyclicality & Seasonality

Demand Patterns: Revenue is expected to fluctuate on a quarter-over-quarter basis due to a limited European commercial effort and a primary focus on the U.S. market. No specific seasonal trends are disclosed.

• Economic Sensitivity: Not explicitly detailed, but general adverse economic conditions impacting customers are identified as a risk.
• Industry Cycles: Not explicitly detailed.

Planning & Forecasting: Not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework: Profound Medical Corp.'s products and operations are subject to extensive government regulation and oversight in the United States (FDA, FFDCA, QSR/QMSR, GCP), the European Union (CE Mark, MDD, New EU MDR), Canada (Health Canada, TPD, Canada MDR, ISO 13485), and other international jurisdictions (e.g., China, South Korea, Saudi Arabia, Malaysia).

• Industry-Specific Regulations: Regulations cover design, development, manufacturing, testing, labeling, clinical trials, product safety, marketing, sales, distribution, post-market surveillance, and recalls. The New EU MDR, effective May 26, 2021, has extended transition periods for MDD certificates until December 31, 2027/2028. UKCA marking will be mandatory for devices placed on the UK market after June 30, 2028/2030. The Food and Drug Omnibus Reform Act of 2022 (FDORA) introduced new requirements for cyber devices and diversity action plans for pivotal trials.
• International Compliance: The company must comply with multi-jurisdictional requirements and is subject to potential enforcement actions for non-compliance.

Trade & Export Controls: Not explicitly detailed beyond general international operations risks.

Legal Proceedings: Profound Medical Corp. is not currently a party to or aware of any legal proceedings that are believed to have a material adverse effect on its business, financial condition, or results of operations.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: (0.6)% (2025), 0% (2024).
• Geographic Tax Planning: Not explicitly detailed.
• Tax Reform Impact: Not explicitly detailed.
• Tax Assets: The company has non-capital loss carry-forwards in Canada of approximately $204.0 million (expiring from 2028 onwards), SR&ED expenditures in Canada of approximately $17.5 million (indefinite carry-forward), and Canadian federal and provincial tax credits of approximately $3.8 million (expiring from 2028 to 2045).
• Valuation Allowance: A valuation allowance of $63.4 million (2025) and $53.6 million (2024) is maintained against deferred tax assets.

Insurance & Risk Transfer

Risk Management Framework: Profound Medical Corp. maintains a comprehensive cybersecurity program aligned with NIST frameworks, focusing on preserving confidentiality, security, and availability of information. It employs tools like phishing training, network monitoring, audits, and vulnerability assessments. The company also has an incident response plan and engages third parties for review.

• Insurance Coverage: The company maintains product liability insurance for clinical trials and commercial use, directors' and officers' liability insurance, and information security risk insurance.
• Risk Transfer Mechanisms: Not explicitly detailed beyond insurance.